Sulthiame

Trade name: Trolone

Small moleculeexperimental

Sultiame is a sulfonamide and inhibitor of the enzyme carbonic anhydrase. It is used as an anticonvulsant and in recent studies showed promise in reducing sleep disordered breathing and other symptoms of obstructive sleep apnea (OSA). — Wikipedia

Clinical trial activity

3 trials · 4 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jun 1, 2006 (NCT00471744)

Timeline

2000s

Jan 1, 2006
Earliest Phase 3 Sponsor(trial)

2010s

Jan 1, 2018
Earliest Phase 1 Sponsor(trial)

2020s

Jan 1, 2021
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Chemistry & pharmacology

Loading structure…

SMILES

NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1

Mol. weight: 290.37 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaSultiame ↗
ChEMBLCHEMBL328560 ↗

Also known as

conadil
conadil
ospolot
ospolot
ospolot
riker 594
riker 594
sulphenyltame
sulphenytame
sulphthiame
sulthiam
sulthiame
sulthiame
sulthiame
sulthiame
sulthiame
sulthiame
sulthiame
sulthiamine
sultiam
sultiam
sultiame
sultiame
sultiame
sultiame
sultiame
trolone
trolone
trolone

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05236842	Phase 2	Nov 23, 2021	Desitin Arzneimittel GmbH
NCT03400189	Phase 1	Feb 12, 2018	Advicenne Pharma, University of Lausanne
NCT00471744	Phase 3	Jun 1, 2006	Ludwig Maximilians University

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Advicenne Pharma	For profit	1	0	1	2018
Desitin Arzneimittel GmbH	For profit	1	1	1	2021
Ludwig Maximilians University	Academic/Hospital	1	1	1	2006
University of Lausanne	Academic/Hospital	1	1	1	2018

4 organizations